Hormonal
Specific gut microbiota metabotypes (such as Equol producers or Urolithin-A producers) are associated with distinct health outcomes, including potential benefits for menopausal symptoms, cardiovascular health, and inflammation, whereas non-producers may see no benefit or different effects.
If you are an 'Equol producer' (converts soy isoflavones to equol), you may experience benefits for menopausal symptoms and cardiovascular health. If you are a 'non-producer', these specific benefits may not occur from the same diet.
The microbial metabolites (phenolic-derived postbiotics) such as equol, urolithins, valerolactones, enterolactone, and enterodiol... can exert differential health effects.
Why this rating
The paper notes 'in vivo evidence on their health effects is still scarce and very limited in humans' for many postbiotics, though Equol has some human trial data.
Source
Where to Look into the Puzzle of Polyphenols and Health? The Postbiotics and Gut Microbiota Associated with Human Metabotypes
Adrián Cortés‐Martín et al. · Molecular Nutrition & Food Research · 2020
DOI 10.1002/mnfr.201900952
More from this paper
- Polyphenols can modulate the gut microbiota composition (acting as prebiotics) by promoting the growth of beneficial bacteria like Lactobacilli and Bifidobacteria, while inhibiting others through antimicrobial activity.Good
- The health benefits of dietary polyphenols are not determined by the polyphenols themselves, but by the specific microbial metabolites (postbiotics) produced by an individual's gut microbiota, leading to significant inter-individual variability in health outcomes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →